Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | HRAS Q61L |
| Therapy | Everolimus + Selumetinib |
| Indication/Tumor Type | lung squamous cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS Q61L | lung squamous cell carcinoma | sensitive | Everolimus + Selumetinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Koselugo (selumetinib) and Afinitor (everolimus) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models, with increased efficacy compared to either agent alone (PMID: 26544513). | 26544513 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26544513) | Mutant HRAS as novel target for MEK and mTOR inhibitors. | Full reference... |